Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chai Ge Antipyretic Oral Solution is a Traditional Chinese Medicine (TCM) formulation developed by Shanghai Yuzhihua Pharmaceutical Technology for the treatment of acute upper respiratory tract infections (URTI). It is specifically indicated for patients presenting with the "wind-heat" pattern, a TCM diagnostic category characterized by symptoms such as fever, sore throat, and headache. The formulation is derived from classical herbal prescriptions, likely featuring *Bupleurum chinense* (Chai Hu) and *Pueraria lobata* (Ge Gen) as primary active components, which are traditionally recognized for their antipyretic, analgesic, and anti-inflammatory properties. The drug has undergone Phase 2 clinical evaluation in China to assess its efficacy and safety in reducing fever and alleviating related clinical symptoms in adult patients compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chai Ge Antipyretic Oral Solution.